
The AstraZeneca (AZN) shares are up today with investors bearing the sentiment that the stock will witness an improved performance thanks to the obvious advantages the Oxford-AZN vaccine has over its rivals.
BioNTech is a biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
BioNTech SE (short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies, and small molecule immunomodulators as treatment options for cancer.
The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process. In 2020, BioNTech’s RNA vaccine candidate for preventing COVID-19 infections, BNT162b2, was in Phase III clinical trials in the United States. On 2 December 2020, temporary Human Medicines Regulations (HMR) authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the UK.
The AstraZeneca (AZN) shares are up today with investors bearing the sentiment that the stock will witness an improved performance thanks to the obvious advantages the Oxford-AZN vaccine has over its rivals.
According to current data, the AstraZeneca PLC stock (LON: AZN) recorded about a 1.3% gain soon after the approval was finalized on top of the previous 3.3% gain.
Pascal Soriot, the Chief Executive of AstraZeneca revealed that the vaccine is as effective as Pfizer and can be a strong protector against the new variant of the virus which is very contagious.